East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Haloperidol Tablets USP, 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg and 20 mg. Aurobindo Pharma’s Haloperidol Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Haldol® Tablets manufactured by Ortho-McNeil Pharmaceutical, Inc.

Haloperidol Tablets are indicated for:

• Use in the management of manifestations of psychotic disorders
• The control of tics and vocal utterances of Tourette’s Disorder in children and adults.